Status:
COMPLETED
Monitoring of Molecular Markers of Artemisinin Resistance Through Repeated Cross-sectional Assessments in DR Congo, Nigeria and Uganda
Lead Sponsor:
Swiss Tropical & Public Health Institute
Collaborating Sponsors:
Clinton Health Access Initiative, Nigeria
Akena Associates Ltd.
Conditions:
Severe Malaria
Eligibility:
All Genders
Up to 5 years
Brief Summary
Currently, 16 African countries include the use of pre-referral rectal artesunate (RAS) in their treatment policies. However, guidelines for RAS use vary widely across countries and inappropriate use ...
Detailed Description
Currently, 16 African countries include the use of pre-referral rectal artesunate (RAS) in their treatment policies and a number of countries have begun to implement RAS. However, guidelines for RAS u...
Eligibility Criteria
Inclusion
- age below 5 years
- enrolled in CARAMAL Project
- history of fever plus danger signs indicative of severe febrile illness / suspected severe malaria, according to local iCCM guidelines
- positive malaria test result by RDT or microscopy
- written informed consent from a parent or guardian
Exclusion
- no current malaria infection
- mixed or mono-infection with a non-P. falciparum species known prior to sample collection
- no permanent residence in project area
Key Trial Info
Start Date :
July 27 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2020
Estimated Enrollment :
916 Patients enrolled
Trial Details
Trial ID
NCT04037332
Start Date
July 27 2018
End Date
July 31 2020
Last Update
January 29 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Health Zone of Kenge
Kenge, Kwango, Democratic Republic of the Congo
2
Health Zone of Ipamu
Ipamu, Kwilu, Democratic Republic of the Congo
3
Health Zone of Kingandu
Kingandu, Kwilu, Democratic Republic of the Congo
4
Adamawa State, selected LGAs
Yola, Adamawa, Nigeria